CDK1 and hepatocellular carcinoma: Preclinical studies have shown that Aurora Kinase A and CDK1/2/5 inhibitors are efficacious in HCC models60–62 and may act synergistically with sorafenib/regorafenib and chemotherapeutic agents59,63,64.